

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 0575/52876/JPW/JML	Serial No. CPA of 08/905,709
		INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)							Applicant David Stern and Ann-Marie Schmidt	
									Filing Date March 23, 2000	Group 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate
EW		5	8	6	4	0	1	8	1/26/99	Morser et al.	530	387.1	
		5	6	8	8	6	5	3	4/16/96	Ulrich, et al.	435	7.1	
↓		5	5	8	5	3	4	4	11/18/97	Vlassara et al.	514	2	

FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation		
													Yes	No	
EW	WO	9	7	3	9	1	2	5	10/23/97	PCT					
↓	WO	9	7	3	9	1	2	1	10/23/97	PCT					
↓	WO	9	7	2	6	9	1	3	7/31/97	PCT					
	WO	9	8	2	2	1	3	8		PCT					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	Brett, J, et al., (1993) "Survey of the distribution of a newly-characterized receptor for AGEs in tissues" <i>Am. J. Pathol.</i> , 143:1699-1712.;													
	Connolly ES, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ: Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. <i>Neurosurg</i> 1996;38:523-532.													
EW	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. <i>Science</i> 272: 689-693.													

EXAMINER <i>Elaine Lazar-Wesley</i>	DATE CONSIDERED 6/21/01
-------------------------------------	----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

attachment # 20

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/52876	Serial No. CPA2 of 08/905,709
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David Stern and Ann-Marie Schmidt	
		Filing Date March 23, 2000	Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	<p>Hori, et al. "The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol." In: The Endothelium in Clinical Practice. January 1997, Chapter 11, pages 311-329;</p> <p>Khoury, J., et al., (1994) "Macrophages adhere to glucose-modified basement membrane via their scavenger receptors" <i>J. Biol. Chem.</i>, 269:10197-10200.</p>		
	<p>Kindy, S. Mark and Rader, J. Daniel (1998) "Reduction in Amyloid A Amyloid Formation in Apolipoprotein-E-Deficient Mice," <i>American Journal of Pathology</i> 152:1387-1395.</p>		
EW	<p>Marui, N., et al. (1993) "VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells" <i>J. Clin. Invest.</i>, 92:1866-1874.</p>		
EW	<p>Nakamura, Y. et al. (1993) Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. <i>Am. J. Pathol.</i> 143 (6) :1649-1656.</p>		
EW	<p>Nakashima Y, Plump A, Raines E, Breslow J, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. <i>Arterioscler Thromb</i> 1994;141:133-140.</p>		
EW	<p>Nepper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. <i>J. Biol. Chem.</i> 267: 14998-15004.</p>		

EXAMINER	<i>Erica Lerner-Werley</i>	DATE CONSIDERED	<i>6/4/01</i>
----------	----------------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/52876/JPW/JML	Serial No. CPA2 of 08/905,709
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David Stern and Ann-Marie Schmidt	
		Filing Date March 23, 2000	Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EWW	Palinski, W. et al. (1995) Immunological evidence for the presence of advanced glycation end products in atherosclerotic lesions of euglycemic rabbits. <i>Arterioscl. Thromb. And Vasc. Biol.</i> 15(5):571-582.
	Park, L., et al. (1998) "Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)" <i>Nature Medicine</i> , 4:1025-1031.
	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. <i>Circulation Supplement</i> . Abstract 3079
	Ritthaler, et al. (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am. J. Path. 146:688-694.
EWW	Schmidt, A. M. et al. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. <i>J. Clin. Invest.</i> 92:2155-2168.
	Schmidt, A. M., et al. (1997) "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes" <i>Circulation Supplement</i> , 96:#194, p. I -37.
	Schmidt, A-M, et al. (1994) "Cellular receptors for advanced glycation end products" <i>Arterioscler. Thromb.</i> , 14:1521-1528.
	Schmidt, A. M., et al (1995) "The Dark Side of Glucose (News and Views)" <i>Nature Medicine</i> , 1:1002-1004.

EXAMINER <i>Elaine Larew - Wesley</i>	DATE CONSIDERED 6/4/01
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.</p>	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/52876/JPW/JML	Serial No. CPA2 of 08/905,709
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David Stern and Ann-Marie Schmidt	
		Filing Date March 23, 2000	Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	Schmidt, A-M, et al. (1994) "Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins" <i>Proc. Natl. Acad. Sci. (USA)</i> , 91:8807-8811.
	Schmidt A-M, Yan S-D, Wautier J-L, Stern DM: Activation of RAGE: a mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis. <i>Circ Res</i> 1999;84:489-497.
EW	Vlassara, H., et al. (1995) "Identification of Galectin-7 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex" <i>Molecular Medicine</i> , 1:634-646.
	Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. <i>Lab. Invest.</i> 70: 138-151.
	Wautier, J. L., et al. (1996) "Receptor-mediated endothelial dysfunction in diabetic vasculopathy: sRAGE blocks hyperpermeability in diabetic rats" <i>J. Clin. Invest.</i> , 97 (1):238-243.
	Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. <i>Circulation Supplement</i> 94(8): #4139. and
	Yan, S-D., et al. (1994) "Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins" <i>J. Biol. Chem.</i> , 269:9889-9897.

EXAMINER <i>Elaine Larson-Wesley</i>	DATE CONSIDERED <i>6/21/01</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	